A London based breast cancer market leader, Endomag which is among one the rapidly growing technology enterprises announced on 30th November 2020 that it raised £15 million or 20 million funding in a Series D round.
The round was led by Draper Esprit, the lead investor in the previous US$ 10.5 million Series C round of Endomag in 2018 and included participation from the existing investors of enterprise Sussex Place Ventures and a few others. The investment brings the company’s total capital to more than US$ 43 million or £32 million. They intend to use the fresh funds for scaling across advanced methods enabled by their offering products like the dSLNB (delayed Sentinel Lymph Node Biopsy) and TAD (Targeted Axillary Dissection). They will also be utilizing the investment in expanding their product range, employees and the current market reach.
The CEO of Endomag, Eric Mayes said, “We feel privileged that we have maintained our growth while supporting doctors, patients and hospitals in these uncertain periods. We are also fortunate that we have such inventors who realized the opportunity we have for leading the market and making a difference or the people with breast cancer.”
Working closely with some experienced breast cancer radiologists and surgeons Endomag has set better standards for breast cancer care. More than 10,000 women have received a raised standardized breast surgery by leading physicians at over 550 hospitals that continuously use the Endomag technology.
MagTeam100 Challenge
The company is committed to improving the previous standards of breast cancer. They assured that the NHS (National Health Service) of the UK was able to maintain important staging treatments involved in cancer during the COVID-19 situation by pledging more than £150,000 Magtrace lymphatic tracer. Recently through their ‘MagTeam100 Challenge” they were able to secure more than £25,000 for breast cancer research. The challenge was to encourage patients to walk, cycle or run 100 miles during the Breast Cancer Awareness Month in October. They had the goals of raising £10,000, for which they needed just 100 registered patients but the event successfully made 180 people complete the challenge!
About Endomag
The medical technology company Endomag was founded in 2007 by Quentin Pankhurst and is headquartered in Cambridge, United Kingdom. They aim at getting better and global standards for cancer care. The products offered include Sentimag probe, Magtrace node markers and Magseed marker and are already used by some leading cancer treatment centers and hospitals. They sell their product through their distributors’’ network across Africa, Australia, Middle East and Europe.
We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!
